CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 38 enrolled
Drug / intervention
CH505TF gp120 +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04607408
NCT04607408Phase 1Completed
CompareCT.gov

A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SE in Healthy, HIV-exposed Uninfected Infants

HIV Vaccine Trials Network·interventional·Posted Oct 29, 2020·Updated Jan 29, 2026

In Brief

A Phase 1 clinical trial evaluating CH505TF gp120, GLA-SE adjuvant, and 1 other intervention for HIV Infections. Completed, enrolled 38 participants across 1 site.

Detailed Summary

This study evaluated the safety and immune response in healthy HIV-exposed and uninfected infants to the protein vaccine, CH505TF gp120, adjuvanted with GLA-SE.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesSouth Africa
CollaboratorsNational Institute of Allergy and Infectious Diseases (NIAID)

Timeline

Phase 1CompletedFinished
202120222023202420252026
First PostedOct 29, 2020
Enrollment StartNov 10, 2020
Primary CompletionJul 24, 2024
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 5.7 years ago

Interventions

CH505TF gp120biological

HIV-1 CH505 transmitted/founder virus Env gp120 immunogen

GLA-SE adjuvantbiological

An oil-in-water stable emulsion (SE) containing the immunological adjuvant Glucopyranosyl Lipid A (GLA)

Placebobiological

Sodium Chloride for Injection, 0.9% USP